Connect with us

Technology

AristaMD Names Keith Pinter, Chief Executive Officer, as Company Continues Longitudinal Care Management in Collaboration with Primary Care

Published

on

Pinter joins an established organization with a 10-year track record of accelerating patient diagnosis and treatment in the primary care setting backed by a board of strategic investors from both the payor and provider segments.

SAN DIEGO, May 29, 2024 /PRNewswire-PRWeb/ — AristaMD, a clinical services and specialty care coordination company that enables primary care providers to manage risk and deliver excellent patient care, announced today that its board of directors has selected Keith Pinter as chief executive officer.

“AristaMD allows primary care providers to offer more comprehensive care, so patients aren’t left in the wild, trying to get the right type of specialist advice quickly, in-network and nearby,” says Keith Pinter, CEO of AristaMD.

Pinter brings over 25 years of experience in healthcare and technology. He has a history of leading companies through rapid organic growth and developing novel business models to meet healthcare organizations’ clinical and financial needs, working within value-based care payment models.

“AristaMD allows primary care providers to offer more comprehensive care, so patients aren’t left in the wild, trying to get the right type of specialist advice quickly, in-network and nearby,” says Keith Pinter, CEO of AristaMD. “They put PCPs at the helm of value-based care by connecting them to a robust specialty network to bend the healthcare cost curve backward. I’m excited to join a team that works closely with its clients to fill a significant gap in managing risk for the entire patient population.”

Pinter joins an established organization with a 10-year track record of accelerating patient diagnosis and treatment in the primary care setting backed by a board of strategic investors from both the payor and provider segments. As a proud and vocal change agent, his strategy is to leverage the company’s technology and deep relationships with risk-bearing entities to accelerate clinical efficacy for patients with high-cost, high-impact conditions, including heart and kidney diseases, musculoskeletal disorders and diabetes management.

“We are excited to welcome Keith to AristaMD,” says John Kuelper, chairman of AristaMD. “His focus on innovation, proven track record in healthcare and commitment to operationalizing value-based care make him an ideal fit to lead AristaMD. Our vision is to leverage our existing services to drive longitudinal specialty care management.”

AristaMD’s clinical care coordination services and network of specialists empower PCPs to deliver rapid access to specialty care, enhance population health management and reduce costs. The company’s innovative approach to risk management includes offering providers the ability to conduct eConsults or video consultations with board-certified specialists covering more than 70 specialties and subspecialties. The PCP’s ability to consult a specialist ensures the patient receives the right care at the right time, often with results delivered within a few hours.

“Since I joined AristaMD in 2016, we have impacted hundreds of thousands of patients with solutions that improve access to specialists and lower healthcare costs,” says Brooke LeVasseur, former CEO of AristaMD. “I move into my role as a strategic advisor for the company, knowing that the talented team at AristaMD will continue to advance our mission to positively impact patient outcomes under Keith’s leadership and creative vision for the future. I am excited to support the team’s efforts as we expand our reach to help partners manage specialty care costs.”

The company augments its specialty care services with clinical expertise, data insights and complementary technology, including referral management and scheduling tools. Using shared data, AristaMD evaluates the patient population served by at-risk primary care organizations. It determines where to deploy these resources and tools to have the greatest impact, allowing its clients to realize significant cost savings, increased care quality, decreased hospital admissions and fewer emergency room visits.

“In the US, a staggering 86% of our health costs are attributed to chronic diseases,” says Pinter. “Managing chronic diseases is a significant challenge for the industry, providers and patients alike. Early detection and effective management are crucial to controlling costs and improving outcomes. PCP enablement solutions, such as eConsults and referral management, are specifically designed to address this pressing challenge.”

Millions of patients in the U.S. wait weeks or even months to visit a specialist due to a growing physician shortage and logistical and administrative obstacles. To solve this critical need, AristaMD’s team of registered nurses curate eConsults on behalf of PCPs to reduce the time to diagnosis and treatment, decrease the patients’ cost and travel burden and eliminate administrative obstacles to accessing specialty advice.

“One-fifth of U.S. GDP goes to healthcare, and we are in the bottom third of outcomes globally,” says Pinter. “Either one of those, in and of itself, is awful. Poor performance in both cost and care and increasing clinician burnout are catastrophic. I feel compelled to improve and lower the cost of care while increasing clinician satisfaction, and I believe AristaMD is a catalyst for solving this predicament.”

Before joining AristaMD, Pinter co-founded Rise Health, a technology-enabled value-based primary care aggregation platform that secured a 9-figure funding commitment in December 2022. He previously served as chief operating officer/chief of staff for Envision Physician Services. Before that, he was part of the leadership team that transformed the third-largest publicly traded hospital system into an industry leader in innovation, growing revenue by over $2 billion. Recognized as 2023 Entrepreneur of the Year by Health Insights, Keith’s focus is on the chronic disease ecosystem.

About AristaMD

AristaMD’s clinical services and specialty care coordination, including eConsult, video consults and referral management tools, empower at-risk providers to deliver rapid access to specialty care, enhance population health management and reduce costs.

The company’s innovative approach to risk management includes offering providers the ability to conduct eConsults or video consultations with board-certified specialists covering more than 70 specialties and subspecialties; schedule in-person specialist visits; trigger automatic follow-up activities critical to patient care and schedule peer-to-peer reviews for insurance authorization. The PCP’s ability to consult a specialist and coordinate follow-up care ensures the patient receives the right care at the right time, often with results delivered within a few hours.

The company augments its specialty care services with clinical expertise, data insights and complementary technology. Using shared data, AristaMD evaluates the patient population served by at-risk primary care organizations. It determines where to deploy the company’s resources and tools to have the greatest impact, allowing its clients to realize significant cost savings, increased care quality, decreased hospital admissions and fewer emergency room visits. For additional information, visit https://www.aristamd.com or follow AristaMD on LinkedIn and X.

About Keith Pinter

Keith Pinter is a change agent and growth-oriented leader with a passion for healthcare and technology. With over two decades of experience in the healthcare provider and technology sectors, Keith has a proven track record of delivering innovative solutions that improve clinical outcomes and patient care.

Keith started his career in technology, building, buying and selling businesses. He then transitioned to healthcare with a mission to bend the healthcare cost curve backward. He co-founded Rise Health, a technology-enabled, value-based primary care aggregation platform. As CEO at Rise Health, Keith led the development of a global risk primary care platform acquisition enterprise, delivering innovative solutions to the healthcare industry.

Prior to his work at Rise Health, Keith served as chief operating officer/ chief of staff for Envision Physician Services, where he was instrumental in growing the organization from $800 million to $6 billion. He was also part of the leadership team that transformed the third-largest publicly traded hospital system into an industry leader in innovation. Keith currently serves on the boards of several healthcare companies, including Moterum Technologies and Prosper RCM Solutions. He has also served on the boards of Cliexa and Accolite, where he was instrumental in the company’s growth and successful mergers and acquisitions (M&A) transactions.

Recognized as 2023 Entrepreneur of the Year by Health Insights, Keith is a visionary leader with a deep understanding of the healthcare industry and a passion for driving change. He is committed to improving clinical and business outcomes through technology enablement and is particularly interested in novel treatment approaches for neurodegenerative diseases after losing his father to two.

Media Contact

Kate McDonald, AristaMD, 1 770-328-4919, kmcdonald@aristamd.com, https://www.aristamd.com

View original content:https://www.prweb.com/releases/aristamd-names-keith-pinter-chief-executive-officer-as-company-continues-longitudinal-care-management-in-collaboration-with-primary-care-302153949.html

SOURCE AristaMD

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Disparities Narrowing Among Patients Undergoing Blood Stem Cell Transplant, Roswell Park Study Reveals

Published

on

By

Historically, some patients with blood cancers have been less likely than others to receive stem cell transplant, also known as bone marrow transplant. Theresa Hahn, PhD, of Roswell Park is lead author of a new study showing that older adults and Black patients are much less likely than people from other groups to receive a blood stem cell transplant.

BUFFALO, N.Y., Sept. 20, 2024 /PRNewswire-PRWeb/ —

Study led by Dr. Theresa Hahn published in JAMA Network OpenNumber of transplants for blood cancers rose from 2009 to 2018Research team analyzed trends in transplant utilization for that period

Every year, more than 22,000 patients in the U.S. undergo a potentially lifesaving blood stem cell transplant — often called a “bone marrow transplant” — for the treatment of hematologic diseases. But historically, some patients with blood cancers have been less likely than others to receive the treatment. Theresa Hahn, PhD, of Roswell Park Comprehensive Cancer Center is lead author of a new study in the journal JAMA Network Open showing that while progress has been made in reducing those disparities, older adults and Black patients are much less likely than people from other groups to receive a blood stem cell transplant.

“This study shows that while progress has been made to reduce disparities among racial and ethnic groups, there’s a need to improve hematopoietic cell transplant utilization rates in older adults and in Black patients of all ages.” — Theresa Hahn, PhD, Roswell Park Comprehensive Cancer Center

The research team analyzed data provided by the Center for International Blood and Marrow Transplant Research (CIBMTR) for 136,280 patients who underwent hematopoietic cell transplant (HCT) in the U.S. between 2009 and 1018, comparing those numbers with the incidence of six blood cancers (acute myeloid and lymphoblastic leukemia, multiple myeloma, Hodgkin and non-Hodgkin lymphoma and myelodysplastic syndrome) in various age, race and ethnic groups the U.S. as reported by the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) Program.

The team found that during that period, the use of HCT increased for the treatment of most blood cancers — and rose among all age, race and ethnic groups.

The researchers also discovered that in the most recent years analyzed, from 2017-2018:

The rate of HCT utilization for blood cancers rose among Hispanic and younger patients to equal the rate of non-Hispanic white patients.Non-Hispanic Black patients had a lower rate of HCT for all six diseases studied.Pediatric, adolescent and young adult patients had a higher rate than adult patients of allogeneic HCT, which involves receiving cells from a healthy donor.

“This study shows that while progress has been made to reduce disparities among racial and ethnic groups, there’s a need to improve hematopoietic cell transplant utilization rates in older adults and in Black patients of all ages,” says Dr. Hahn, Professor of Oncology in the Department of Cancer Prevention and Control at Roswell Park and the study’s first author.

The research team also include Dr. Hahn’s Roswell Park colleague Megan Herr, PhD, and collaborators from the Medical College of Wisconsin, Milwaukee; the CIBMTR; and the Mayo Clinic.

From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. Driven to eliminate cancer’s grip on humanity, the Roswell Park team of 4,000 makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Founded in 1898, Roswell Park was among the first three cancer centers nationwide to become a National Cancer Institute-designated comprehensive cancer center and is the only one to hold this designation in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email ASKRoswell@RoswellPark.org.

Media Contact

Julia Telford, Roswell Park Comprehensive Cancer Center, 716-845-4919, julia.telford@roswellpark.org, roswellpark.org

View original content to download multimedia:https://www.prweb.com/releases/disparities-narrowing-among-patients-undergoing-blood-stem-cell-transplant-roswell-park-study-reveals-302254312.html

SOURCE Roswell Park Comprehensive Cancer Center

Continue Reading

Technology

IFIC Monthly Investment Fund Statistics – August 2024

Published

on

By

Mutual fund and exchange-traded fund (ETF) assets and sales

TORONTO, Sept. 20, 2024 /CNW/ – The Investment Funds Institute of Canada (IFIC) today announced investment fund net sales and net assets for August 2024.

Mutual fund assets totalled $2.145 trillion at the end of August, up by $7.7 billion or 0.4 per cent since July. Mutual fund net sales were $2.4 billion in August.

ETF assets totalled $464.0 billion at the end of August, up by $5.9 billion or 1.3 per cent since July. ETF net sales were $4.3 billion in August.

August insights

Mutual fund net sales were positive for the second consecutive month.Year to date, mutual funds experienced inflows of $3.6 billion, compared to outflows of $23.2 billion over the same period last year.Money market funds experienced the largest single month of outflows since November 2021, largely the result of outflows from high-interest saving account funds.Year to date, ETFs experienced inflows of $41.6 billion, which is 82 per cent higher than inflows over the same period last year.

Mutual fund net sales/net redemptions ($ millions)*

Asset class

Aug 2024

Jul 2024

Aug 2023

YTD 2024

YTD 2023

Long-term funds

     Balanced

(1,383)

(1,025)

(4,750)

(21,271)

(31,002)

     Equity

1,093

2,088

(2,152)

1,212

(13,584)

     Bond

2,538

3,307

(427)

16,339

8,591

 Specialty

547

800

366

5,157

2,642

Total long-term funds

2,795

5,169

(6,963)

1,436

(33,353)

Total money market funds

(420)

31

1,302

2,194

10,142

Total

2,375

5,200

(5,661)

3,630

(23,211)

 

Mutual fund net assets ($ billions)* 

Asset class

Aug 2024

Jul 2024

Aug 2023

Dec 2023

Long-term funds

     Balanced

964.3

962.9

893.6

904.3

     Equity

823.5

821.3

701.3

714.4

     Bond

268.7

264.7

234.5

242.3

     Specialty

34.1

33.7

25.8

27.0

Total long-term funds

2,090.6

2,082.6

1,855.2

1,888.0

Total money market funds

54.4

54.8

45.7

50.7

Total

2,145.0

2,137.4

1,900.9

1,938.7

 

*

See below for important information about this data.

ETF net sales/net redemptions ($ millions)*

Asset class

Aug 2024

Jul 2024

Aug 2023

YTD 2024

YTD 2023

Long-term funds

     Balanced

464

558

140

3,305

1,103

     Equity

1,748

2,380

330

22,822

6,776

     Bond

1,176

1,463

641

13,359

7,085

 Specialty

991

254

(280)

1,288

1,047

Total long-term funds

4,378

4,655

832

40,775

16,011

Total money market funds

(94)

310

1,051

863

6,864

Total

4,285

4,965

1,883

41,638

22,875

ETF net assets ($ billions)* 

Asset class

Aug 2024

Jul 2024

Aug 2023

Dec 2023

Long-term funds

     Balanced

20.2

19.6

13.9

15.1

     Equity

290.5

286.6

219.7

232.5

     Bond

109.2

107.7

86.3

94.6

     Specialty

17.8

17.7

11.7

14.4

Total long-term funds

437.8

431.7

331.6

356.7

Total money market funds

26.3

26.4

23.1

25.3

Total

464.0

458.1

354.7

382.0

 

*

See below for important information about data.

IFIC direct survey data (which accounts for approximately 87 per cent of total mutual fund industry assets and approximately 80 per cent of total ETF industry assets) is complemented by estimated data to provide comprehensive industry totals.

IFIC makes every effort to verify the accuracy, currency, and completeness of the information, however, IFIC does not guarantee, warrant, represent or undertake that the information provided is correct, accurate or current.

© The Investment Funds Institute of Canada. No reproduction or republication in whole or in part is permitted without permission.

* Important information about investment fund data

Mutual fund data is adjusted to remove double counting arising from mutual funds that invest in other mutual funds.Starting with January 2022 data, ETF data is adjusted to remove double counting arising from Canadian-listed ETFs that invest in units of other Canadian-listed ETFs. Any references to IFIC ETF assets and sales figures prior to 2022 data should indicate that the data has not been adjusted for ETF of ETF double counting.The balanced funds category includes funds that invest directly in a mix of stocks and bonds or obtain exposure through investing in other funds.Mutual fund data reflects the investment activity of Canadian retail investors.ETF data reflects the investment activity of Canadian retail and institutional investors.

About IFIC

The Investment Funds Institute of Canada is the voice of Canada’s investment funds industry. IFIC brings together 150 organizations, including fund managers, distributors and industry service organizations to foster a strong, stable investment sector where investors can realize their financial goals. By connecting Canada’s savers to Canada’s economy, our industry contributes significantly to Canadian economic growth and job creation. Learn more about IFIC

SOURCE The Investment Funds Institute of Canada

Continue Reading

Technology

VINFAST REPORTS UNAUDITED SECOND QUARTER 2024 FINANCIAL RESULTS

Published

on

By

SINGAPORE, Sept. 20, 2024 /PRNewswire/ — VinFast Auto Ltd. (“VinFast” or the “Company”) (Nasdaq: VFS), a subsidiary of Vingroup JSC, and Vietnam’s only pure-play electric vehicle manufacturer, today announced its unaudited financial results for the second quarter ended June 30, 2024.

VinFast delivered 13,172 EVs in Q2, up by 44% QoQ and 43% YoY, bringing its delivery total for the first half of 2024 to 22,348 vehicles, a 101% increase compared to the same period last year.The Company recorded $357 million in revenue for Q2, up by 33% QoQ and 9% YoY.Vietnam, where momentum is accelerating, will play a key role in driving VinFast’s revenue in the remainder of 2024.

Madam Thuy Le, Chairwoman of VinFast, said: “We remain focused on our mission to contribute to a sustainable future for everyone. Our strategy is unchanged with regards to being a vertically-integrated green mobility solutions company providing high quality and good-value electric vehicles. With the delivery of VF 3 starting in Q3, we have completed the development of all 7 e-SUV models.”

Ms. Lan Anh Nguyen, Chief Financial Officer of VinFast, added: “Q2 of 2024 aligned with our forecasts, driven in large part by the increasing demand for VinFast’s EVs in Vietnam. This growth in our home market has been crucial in advancing our mission to promote EV adoption and green mobility. The momentum we’ve built in Vietnam has laid a solid foundation for our strong position in this key market to continue thriving.”

VinFast EV Deliveries Rose 44% QoQ and Revenue Grew 33% QoQ

During the quarter, VinFast delivered 13,172 vehicles, a 44% increase compared to the previous quarter and a 43% increase year-over-year. This brings total deliveries for the first half of 2024 to 22,348 vehicles, representing a 101% increase compared to the same period last year. 

One of the key drivers behind this growth was the increasing adoption of electric vehicles in the Vietnamese market, where VinFast recorded a 108% year-over-year increase in B2C deliveries in Q2.

VinFast reported $357 million in revenue in Q2, up by 9% year-over-year and by 33% quarter-over-quarter. 

The Company’s gross loss for Q2 was ($224) million, equivalent to a gross margin of (62.7%). This was primarily due to an impairment charge on Net Residual Value (NRV) of $104 million, compared to $5 million in Q1.

Expanding Global Footprint to Drive Sales

VinFast’s strategic expansion through dealership network has shown progress.

As of August 31, VinFast had 155 showrooms across all markets, of which around 70% were dealerships.

Strengthening Presence in Key Markets

Vietnam

VinFast achieved its highest year-over-year growth for Vietnam in the first half of 2024. The VF 5 model has been instrumental in driving the Company’s strong sales performance, securing the VF 5’s position as a domestic leader in its segment. Additionally, the Company began delivering its highly anticipated VF 3, VinFast’s mini electric SUV, in the third quarter of 2024.

North America

In the second quarter of 2024, VinFast continued to build its foundation in the U.S. by introducing its products and strategies to key dealerships. To bolster brand awareness, VinFast expanded customer outreach through its dealer network and established a Dealer Advisory Council to gain valuable insights. As of the second quarter, VinFast now operates in eight states, California, Connecticut, Florida, Kansas, Kentucky, North Carolina, New York, and Texas, with a combined network of dealer stores and VinFast-owned showrooms.

In Canada, VinFast recorded 15% quarter-over-quarter growth in the second quarter and is seeing this momentum continue in the third quarter, with July and August seeing its highest delivery levels for North America in the past year.

Southeast Asia

VinFast entered the Indonesian market less than six months ago and has since established 15 showrooms across major cities, including Jakarta and Surabaya. VinFast began delivering its first batch of VF e34 electric vehicle during the third quarter of 2024, making Indonesian customers the first globally to receive right-hand drive VinFast EVs. VinFast also broke ground its completely knocked down (CKD) facility in Indonesia.

VinFast’s innovative battery subscription offer has been a key driver of sales in Indonesia, accounting for nearly 100% of its total sales and orders. This program has also garnered positive feedback in the Philippines, further validating its commitment to making electric vehicles more accessible.

Building on the positive response from dealers in the Philippines, VinFast is eager to introduce additional models to the market in the coming months, further expanding its footprint and product offerings in the region.

Outlook for the Remainder of 2024

VinFast reaffirms its target to deliver approximately 80,000 units in 2024.

Vietnam is expected to play a key role in driving revenue for the remainder of 2024. The growing success of the VF 5 model, along with VinFast’s extensive charging infrastructure, flexible battery subscription program, and strong after-sales services, are expected to reinforce its leadership position in the Vietnamese electric vehicle market.

While international markets continue to face near-term challenges, they remain integral to VinFast’s longer-term growth strategy as the company expands its global brand and distribution network.

VinFast remains committed to its mission of accelerating the global shift to sustainable electric mobility through continuous innovation, product expansion, and market presence./.

Conference Call

The Company’s management will host its second quarter 2024 earnings conference call at 8:00 AM U.S. Eastern Time on September 20, 2024.

Live Webcast: https://edge.media-server.com/mmc/p/urnhoxtg
For additional information, please visit https://vinfastauto.us/investor-relations/
Investor Relations – Email: ir@vinfastauto.com
Media Relations – Email: info@vingroup.com

About VinFast 

VinFast (NASDAQ: VFS), a subsidiary of Vingroup JSC, one of Vietnam’s largest conglomerates, is a pure-play electric vehicle (“EV”) manufacturer with the mission of making EVs accessible to everyone. VinFast’s product lineup today includes a wide range of electric SUVs, e-scooters, and e-buses. VinFast is currently embarking on its next growth phase through rapid expansion of its distribution and dealership network globally and increasing its manufacturing capacities with a focus on key markets across North America, Europe and Asia. Learn more at www.vinfastauto.us

Forward-Looking Statements

Forward-looking statements in this announcement, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955. These statements include statements regarding our future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of VinFast, market size and growth opportunities, competitive position and technological and market trends and involve known and unknown risks that are difficult to predict. As a result, our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the effect of the consummation of the business combination and the public listing of the Company’s securities on its business relationships, performance, financial condition and business generally, (ii) the risk that the Company’s securities may experience a material price decline and volatility in the price of such securities due to a variety of factors, (iii) the adverse impact of any legal proceedings and regulatory inquiries and investigations on the Company’s business, (iv) the Company’s potential inability to maintain the listing of its securities on Nasdaq, (v) the risk associated with the Company’s limited operating history, (vi) the ability of the Company to achieve profitability, positive cash flows from operating activities and a net working capital surplus, (vii) the ability of the Company to fund its capital requirements through additional debt and equity financing under commercially reasonable terms and the risk of shareholding dilution as a result of additional capital raising, if applicable, (viii) risks associated with being a new entrant in the EV industry, (ix) the risks of the Company’s brand, reputation, public credibility and consumer confidence in its business being harmed by negative publicity, (x) the Company’s ability to successfully introduce and market new products and services, (xi) competition in the automotive industry, (xii) the Company’s ability to adequately control the costs associated with its operations, (xiii) the ability of the Company to obtain components and raw materials according to schedule at acceptable prices, quality and volumes acceptable from its suppliers, (xiv) the Company’s ability to maintain relationships with existing suppliers who are critical and necessary to the output and production of its vehicles and to create relationships with new suppliers, (xv) the Company’s ability to establish manufacturing facilities outside of Vietnam and expand capacity in a timely manner and within budget, (xvi) the risk that the Company’s actual vehicle sales and revenue could differ materially from expected levels based on the number of reservations received, (xvii) the demand for, and consumers’ willingness to adopt, EVs, (xiii) the availability and accessibility of EV charging stations or related infrastructure, (xix) the unavailability, reduction or elimination of government and economic incentives or government policies which are favorable for EV manufacturers and buyers, (xx) failure to maintain an effective system of internal control over financial reporting and to accurately and timely report the Company’s financial condition, results of operations or cash flows, (xxi) battery pack failures in the Company or its competitor’s EVs, (xxii) failure of the Company’s business partners to deliver their services, (xxiii) errors, bugs, vulnerabilities, design defects or other issues related to technology used or involved in the Company’s EVs or operations, (xxiv) the risk that the Company’s research and development efforts may not yield expected results, (xxv) risks associated with autonomous driving technologies, (xxvi) product recalls that the Company may be required to make, (xxvii) the ability of the Company’s controlling shareholder to control and exert significant influence on the Company, (xxiii) the Company’s reliance on financial and other support from Vingroup and its affiliates and the close association between the Company and Vingroup and its affiliates, (xxix) conflicts of interests with or any events impacting the reputation of Vingroup affiliates or unfavorable market conditions or adverse business operations of Vingroup and Vingroup affiliates and (xxx) other risks discussed in our reports filed or furnished to the Securities and Exchange Commission.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. You are cautioned not to place undue reliance on any forward-looking statements, which are made only as of the date of this announcement. VinFast does not undertake or assume any obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If VinFast updates one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. The inclusion of any statement in this announcement does not constitute an admission by VinFast or any other person that the events or circumstances described in such statement are material. Undue reliance should not be placed upon the forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/vinfast-reports-unaudited-second-quarter-2024-financial-results-302254421.html

SOURCE VinFast

Continue Reading

Trending